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Abstract: In recent years, many studies have highlighted the consistent finding of tramadol (TRA)
in the effluents from wastewater treatment plants (WTPs) and also in some rivers and lakes in
both Europe and North America, suggesting that TRA is removed by no more than 36% by specific
disinfection treatments. The extensive use of this drug has led to environmental pollution of both
water and soil, up to its detection in growing plants. In order to expand the knowledge about
TRA toxicity as well as the nature of its disinfection by-products (DBPs), a simulation of the waste
treatment chlorination step has been reported herein. In particular, we found seven new by-products,
that together with TRA, have been assayed on different living organisms (Aliivibrio fischeri, Raphidocelis
subcapitata and Daphnia magna), to test their acute and chronic toxicity. The results reported that
TRA may be classified as a harmful compound to some aquatic organisms whereas its chlorinated
product mixture showed no effects on any of the organisms tested. All data suggest however that
TRA chlorination treatment produces a variety of DBPs which can be more harmful than TRA and a
risk for the aquatic environment and human health.
Keywords: tramadol; chlorination; disinfection by-products (DBPs); chlorine derivatives; disinfection
treatments; acute and chronic toxicity tests
1. Introduction
According to information available to the International Narcotics Control Board (INCB), the loose
legislation in China, India and Sri Lanka allows mass production, not always legal, of tramadol (TRA).
Generally, the drug arrives by ship to the Mediterranean where Italy and Greece are important points
of disembarkation and distribution, but above all the main flow is towards Libya. The traffic then
continues to Egypt and ends up in the main Middle Eastern countries, where in many countries it is
not considered illegal. The powerful opioid, which in Europe can only be sold with a non-repeatable
medical prescription, is called the “drug of the fighter”, costs a few euros per tablet and militias
take it above all to endure the pain of wounds. It is estimated that world traffic drives a turnover of
1.39 billion dollars a year. The total amount of TRA used worldwide in the period from 1990 to 2009 was
calculated to be 11,758 million of defined daily doses (1 DDD is equal to 300 mg) [1]. There is evidence
of increasing traffic in TRA preparations to North and West Africa, as indicated by recent large seizures
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of such preparations in these regions. Egyptian authorities seized about 120 million tablets containing
TRA in 2011 and about 320 million tablets in the first quarter of 2012. Saudi Arabia also reported
increasing amounts of seizures of preparations containing TRA. In Gaza 2.5 million of TRA pills were
seized in 2009, compared to 550,000 in 2008 [2]. In Benin, Ghana, Senegal and Togo (West Africa), large
amounts of TRA preparations, totalling more than 132 tons of such preparations, were seized between
February and October 2012. The preparations had been concealed in sea containers sent from India
and were intercepted by the local law enforcement authorities [3]. In Wales, medical prescriptions are
estimated at 2145 kg of product per year and as many as 25,000 kilos only in Germany [4,5].
TRA in 2013 was identified in a Cameron tree called Sarcocephalus latifolia [6]. Three years
ago, some German and Cameroonian researchers demonstrated its anthropogenic nature through
measurements of 14C content [7]. Evidently, the massive and illegal use as doping agent, both for
humans and animals in order to withstand unsustainable workloads at temperatures above 40 ◦C,
have led to consistent environmental pollution of water and soil. In some cases, the tests revealed the
presence of TRA also in plants other than S. latifolia and in public wells, at alarming concentrations [8].
According to their physicochemical properties, TRA is expected to remain mainly in the water phase,
considering its high water solubility and that volatilization is negligible because of the low Henry
coefficients. Furthermore, its n-octanol/water partition coefficient indicates a tendency to remain in the
water phase instead of accumulation in sewage sludge or in aquatic organisms. Could be interesting to
consider the long-term side effects of TRA in humans, animals and the environment [9].
In recent studies, TRA has been detected in effluents from wastewater treatment plants (WWTPs)
and in some rivers and lakes in both Europe and North America [10–12]. Several reports proved
that 15–35% of the used product is excreted via the urine together with 15% of the desmethylated
product, which is the major metabolite [10]. In general, the metabolic fate of TRA is quite complex
with about 12 conjugated and 11 non-conjugated products [13–15]. The presence and fate of TRA
and other 55 pharmaceuticals, endocrine disruptors, illicit drugs and personal care products (PPCPs)
were investigated in the South Wales region of the UK [16], where it has been estimated an average
consumption of 1654 mg/day per 1000 people, based on the data provided by the English National
Health Service (NHS) of 2010 [12]. In this regard, it was reported that in the UK Cilfynydd WWTP
influents, the maximum TRA concentrations was 89,026 ng/L and unexpectedly into the effluents was
around 97,616 ng/L [16,17]. However, there is only a limited data available about the reduction of
this compound and its metabolites in the WWTPs, estimating that no more than 36% of the TRA is
removed by tricking filter and activated sludge treatment [18].
There are no precise data on the removal of TRA from wastewaters [19,20] and, in particular,
by aqueous chlorination, only a paper by Cheng et al. [21] which reported the formation of a variety
of chlorinated derivatives identified only by mass spectrometry. In general, during chlorination
disinfection treatment, chorine reacts with natural organic matter and other organic compounds to
form so-called disinfection by-products (DBPs) [22–24]. Several studies have shown that DBPs are
usually more resistant to degradation and can be more toxic than their parent drugs [25–28]. In this
paper, the degradation pathway of TRA was investigated by simulating the chlorination process
normally used in a wastewater treatment plant to reduce similar emerging pollutants. The products
obtained were identified and their acute and chronic toxicity assayed on different aquatic organisms
(Aliivibrio fischeri, Raphidocelis subcapitata and Daphnia magna), using TRA for comparision.
2. Results and Discussion
2.1. Chlorination Data
Chlorination of TRA produced the disinfection by-products BP1–BP7 (Scheme 1) that were
isolated by chromatography and identified on the basis of their physical features. Compound BP1
has the molecular formula C16H24ClNO2 according to the presence of peaks at m/z 297.81 [M]+ and
299.80 [M + 2]+ in the EI mass spectrum and sixteen carbon signals in the 13C-NMR spectrum. The
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mass spectrum showed also a fragment at m/z 262.37 due to the loss of a chlorine and a fragment at
m/z 246.37 due to the loss of oxygen plus chlorine atoms bound to the C-1 benzyl carbon.Molecules 2019, 24, x FOR PEER REVIEW  3 of 12 
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signals of the methoxyl, H-2 and H-7 protons (δ 3.85, 1.84, 2.06/2.40, respectively) in addition to a
peak at δ 2.13/2.15 integrable for six protons and related to the two methyls on the nitrogen atom.
Assignments of protons to carbons were based on a HSQC experiment, while the HMBC spectra
allowed the attribution of the signals of the two quaternary carbons to δ 152.00 and 159.98 to C-1’ and
C-3’ carbons, respectively. The compound was identified as the hypochlorite corresponding to the
starting product.
BP2 has molecular formula C14H21NO3 according to the presence of the molecular ion at m/z
251.30 [M]+ in the EI mass spectrum and fourteen carbon signals in the 13C-NMR spectrum. In the 1H
NMR the four aromatic ring protons seen at δ 6.81, 7.00, 7.05 and 7.29 correlated in the HSQC spectrum
to the carbons at δ 111.97, 116.68, 110.88 and 129.26, respectively. The 13C-NMR spectrum, besides the
signals of the protonated carbons, showed two quaternary carbons signals at δ 159.52 and 148.48 that
HMBC experiments allowed to assign the first one to C-3′ and the latter to C-1′. The DEPT spectrum
showed the presence of two methines at δ 2.15 and 4.45, identified as H-2 and H-7, respectively, whose
protons were correlated with each other in the COSY spectrum and both correlated to C-1 carbon in
the HMBC spectrum, at δ 77.07. In the last spectrum the methine H-2 was correlated to the aromatic
carbon C-1′, as well as to the C-3, C-6 and C-7 carbons, at δ 26.23, 40.38 and 67.85 respectively, while
the methine H-7 was correlated to C-2 and C-3, at δ 32.70 and 26.23, respectively.
BP3 had a pseudo-molecular ion at m/z 234.35 [M]+ in the EI mass spectrum and fourteen carbon
signals in the 13C-NMR spectrum, which correspond to the molecular formula C14H18O3. The 1H-
NMR indicated the absence of the three carbons bounded to the nitrogen and the presence of two
singlet signals at δ 9.61 e 6.65. In the HSQC spectrum these last two signals were correlated to the
carbons at δ 192.90 e 150.02, respectively. In the HMBC spectrum the proton a δ 9.61 was correlated
to the signals at δ 150.02, 143.50 e 21.44, identified as C-2, C-3 and C-4 carbons, respectively, while
the proton a δ 6.65 was correlated to the carbons C-3 and C-4 and to the signals at δ 192.90 and 77.10,
identified as carbons C-7 and C-1, respectively.
BP4 had a molecular ion at m/z 261.34 [M]+ in the EI mass spectrum and sixteen carbon signals
in the 13C-NMR spectrum, which correspond to the molecular formula C16H23NO2. The 1H-NMR
indicated the absence of one of the two methyls bound to the nitrogen and the presence of a signal
at δ 3.62 and 4.20, correlated in a HSQC spectrum at the carbon δ 82.40 (C-10). The DEPT spectrum
confirmed the methylene nature of this signal and the HMBC spectrum indicated the correlation of
the protons with the signals at δ 77.10, 56.12 and 40.36, identified as the C-1, C-7 and C-9 carbons,
respectively, and the correlation of the corresponding carbon with the H-9 methyl protons at δ 2.01
and with the H-7 protons at δ 2.42 and 2.54.
BP5 had a molecular ion at m/z 342.79 [M]+ and 344.80 [M + 2]+ in the EI mass spectrum and
seventeen carbon signals in the 13C-NMR spectrum, which correspond to the molecular formula
C17H23ClO5. The 1H-NMR showed the presence of four protons of aromatic ring and a methoxyl
groups. The 13C-NMR spectrum showed the presence of the signals of the aromatic ring and of its
methoxyl group as well as other ten signals, of which two carbonyls at δ 199.69 and 208.13. The
remaining height signals in a DEPT experiment were identified as one methyl, five methylenes, one
methine and one quaternary carbon, whose corresponding protons were identified by an HSQC
spectrum. The carbon at δ 199.69, identified as C-1, was correlated in an HMBC spectrum to the two
aromatic protons H-2′ and H-6′, at δ 7.51 and 7.56, respectively, and to the signals at δ 3.04 and 1.83,
identified as protons H-2 and H-3, respectively, that were coupled together in a COSY spectrum. The
COSY spectrum also showed the correlation between the signals at δ 1.80 and 2.35, of which the first
one was identified as relative to the protons H-4, correlated in the same COSY spectrum to the protons
H-3, and the second one, identified as relative to protons H-5. The protons H-5 were correlated in
a HMBC experiment to signals at δ 96.27 and 74.07, identified as carbons C-6 and C-7, respectively.
In the same HMBC spectrum the quaternary carbon at δ 208.13 was correlated with the signal of the
methyl protons at δ 2.28, with those of the methylene at δ 2.95 and 3.18 and with the methine at δ 4.39,
identified as protons H-10, H-8 and H-7, respectively.
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BP6 had a molecular ion at m/z 277.38 [M]+ in the EI mass spectrum and sixteen carbon signals in
the 13C-NMR spectrum, which could correspond to the molecular formula C16H23NO3. The 1H- NMR
indicated the presence of a signal of an aldehyde function at δ 7.79 and the absence of one of the two
methyls bound to the nitrogen. The HSQC spectrum showed the correlation of the aforementioned
proton at low fields with carbon at δ 163.13 and the HMBC spectra showed its correlations with the
signals at δ 50.68 and 29.76, identified as the carbons C-7 and C-9, respectively, confirming that the
isolated product was the oxidized TRA to one of the two methyls.
BP7 had a molecular ion at m/z 276.31 [M]+ in the EI mass spectrum, beyond that 246.30 and
219.29 due to the loss of NO and NO and HCN; moreover the 13C-NMR spectrum showed fifteen
carbon signals, which could correspond to the molecular formula C15H20N2O3. The 1H-NMR indicated
the absence of the two methyls bound to the nitrogen, confirmed the presence of the signals of aromatic
ring and of methoxyl group and the presence of two pairs of signals at δ 2.66 and 2.70 and at δ 2.73 and
2.75, correlated in an HSQC spectrum to the signals at 67.40 and 54.00, respectively. In correspondence
of these last two signals the DEPT spectrum confirmed the presence of two methylenes, as well as two
methines at δ 44.53 and 25.81, bound in the HSQC spectra to the protons at δ 2.15 and 1.95, respectively.
The methylene protons at δ 2.66/2.70 were correlated in an HMBC spectrum with the signals a δ 25.81,
44.53 and 26.11, identified as the carbons C-3, C-2 and C-4, while the methylene protons at δ 2.73/2.75
were correlated with the carbons C-2 and C-3 and with the signal a δ 77.50, identified as the carbon
C-1. A possible mechanism for obtaining the products BP1–BP7 is shown in Scheme 1.
2.2. Ecotoxicity Data
Ecotoxicity is essential to determine the potential hazard and risk of emerging contaminants.
Based on literature reviews, TRA-associated ecotoxicity is scarcely reported [29] and its transformation
by-products after chlorination have not been reported elsewhere. Published findings [29,30] indicated
that TRA induces only negligible effects with half maximal effective concentration (EC50) values up to
100 mg/L. Bergheim et al. [30] found that a concentration of 374 mg/L TRA induced a 50% growth
inhibition in Pseudomonas putida bacterial strain. Another study showed slight TRA toxicity in Daphnia
magna [29] with an EC50 value of 170 mg/L. Effect concentration (EC50) of TRA, its chlorination
mixture and disinfection by-products on A. fischeri, R. subcapitata and D. magna organisms is presented
in Table 1. Considering the risk classification system on EC50 values [31], toxicity data (D. magna (24 h),
R. subcapitata and A. fischeri) were combined and ranked in four main groups of samples as: (i) very
toxic (EC50 < 1 mg/L); (ii) toxic (EC50 1–10 mg/L); harmful (EC50 10–100 mg/L); and (iii) not harmful
(EC50 >100 mg/L). Results of parental compound showed that the relative sensitivity order was R.
subcapitata > D. magna > A. fischeri. In particular, no toxic effect was observed for TRA with A. fischeri.
In fact, luminescence was measurably enhanced during contact with TRA, probably because it was
consumed as a nutrient by the bacteria. The highest TRA concentration used was 100 mg/L, thus it may
be inferred that EC50 value exceeds 100 ppm. TRA-associated EC50 was estimated as 88.5 mg/L and
87.1 mg/L for D. magna and R. subcapitata respectively. According to the EU Directive 93/67/EEC [31],
the TRA may be classified as harmful to aquatic organisms, as according to the European regulation
EC50 values less than 100 mg/L gives a classification of “Harmful” to aquatic organisms [32]. This
means that TRA pseudopersistence will be a concern, and in some cases, it might have toxicity.
A comparison of our EC50 value for TRA in D. magna with published data [29] has been done,
but some discrepancies were observed, the mismatch being probably due to differences between the
test protocols used [33,34]. The same bioassays were carried out to assess the ecotoxicological effects of
TRA chlorinated mixture and the obtained data demonstrated that no effect was induced in bacteria,
while micro-crustaceans and algae were more sensitive to the mixture than the parent compound with
EC50 values of about 50 mg/L. A comparison among the adverse effects of TRA mixture, denotes that
TRA degradation does not follow a toxicity decrease with a possible synergistic interaction between
the byproducts. In addition, we performed ecotoxicity tests for the BP1–BP7 isolated products and we
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found a multiple effect of chlorination on the ecotoxicity profile in some of these byproducts; we also
noticed a higher toxicity in A. fischeri compared to TRA as well as the mixture.
Products BP6 and BP2 were less toxic than TRA, with EC50 values ranged to 250 mg/L and
450 mg/L and could be classified as a not harmful compounds. BP4, BP5, BP1, BP3 and BP7 were
found more toxic compared to TRA, suggesting that the adverse effects of oxidized species depends
on the extent of oxidation [35]. According to the EU risk classification BP4, BP5, BP1, BP3 and BP7
are classified as harmful compounds. The relative toxicity order was BP4 > BP5 > BP1 > BP3 > BP7.
In particular, the EC50 data were ranging 81–117 mg/L for BP7, 26–66 mg/L for BP1 and 28–34 mg/L
for BP4. In these cases, the degree of oxidation was also found to increase the toxicity of by-products
suggesting that TRA oxidation has the potential to produce by-products, which can be more harmful
than TRA.
Table 1. Ecotoxicity of TRA, chlorinated mixture and by-products (all values in mg/L ± 95% IC).
Compound A. fischeri (30 min) R. subcapitata (72 h) D. magna (24 h)
TRA N.E. up to 100 87.1 (81.8 to 92.7) 88.5 (81.9 to 95.4)
Mix N.E up to 100 58.7 (51.2 to 67.4) 54.4 (48.6 to 60.8)
BP1 40.3 (36.5 to 44.5) 66.2 (63.5 to 69.0) 26.1 (23.3 to 27.4)
BP2 282.6 (266.5 to 299.6) 322.2 (292.8 to 354.7) 357.9 (301.5 to 370.4)
BP3 52.8 (50.9 to 58.1) 71.7 (65.3 to 78.9) 63.4 (60.4 to 65.8)
BP4 34.4 (31.6 to 37.4) 32.2 (32.3 to 38.4) 28.5 (20.4 to 25.7)
BP5 45.6 (41.2 to 49.3) 44.7 (39.6 to 58.6) 38.6 (35.3 to 42.1)
BP6 252.8 (212.7 to 300.6) 447.4 (413.1 to 484.6) 402.3 (398.9 to 407.8)
BP7 81.3 (76.4 to 86.5) 117.8 (105.7 to 131.2) 106.5 (90.7 to 108.1)
3. Materials and Methods
3.1. Chemicals
TRA (1, 99.3%) was purchased from Sigma Aldrich (Milan, Italy). All the other chemicals and
solvents were purchased from Fluka (Saint-Quentin Fallavier, France), with HPLC grade and were
used as received.
3.2. Chlorination Reaction
3.2.1. Apparatus
Column chromatography (CC) was carried out on Kieselgel 60 (230–400 mesh, Merck, Darmstadt,
Germany). HPLC was performed on a Shimadzu LC-8A system using a Shimadzu SPD-10A VP UV-VIS
detector (Shimadzu, Milan, Italy). Semipreparative HPLC was performed using a RP Gemini C18-110A
preparative column (10 µm particle size, 250 mm × 21.2 mm i.d., Phenomenex, Bologna, Italy) column
with a flow rate of 5.0 mL min−1. 1H- and 13C-NMR spectra were recorded on an INOVA-500 NMR
instrument (Varian, Milan, Italy, 1H at 499.6 MHz and 13C at 125.62 MHz), referenced in ppm to residual
solvent signals (CDCl3, at δH 7.27 and δC 77.0) at 25 ◦C. Proton-detected heteronuclear correlations
were measured using a gradient heteronuclear single-quantum coherence (HSQC), optimized for
1JHC = 155 Hz, a gradient heteronuclear multiple bond coherence (HMBC), optimized for nJHC = 8 Hz.
Electronic Impact Mass Spectra (EI-MS) were obtained with a QP-5050A EI 70 eV spectrometer
(Shimadzu).
3.2.2. Chlorination Procedure and Product Isolation
TRA (1 g, 6.17 mmol) dissolved in milliQ water (1 L) was treated for 30 min with 10% hypochlorite
(molar ratio TRA: hypochlorite 1:6; concn, spectroscopically determined λmax 292 nm, ε 350 dm3/mol
cm) at room temperature [36]. The pH of the solution, measured by a pH-meter at five minute intervals,
rose from the initial pH 8.5 to 9.8, after 5 min, and it remained at this value during the reaction time.
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After 30 min, the solution, quenched by sodium sulfite excess, was concentrated by lyophilization
and extracted with ethyl acetate. The ethyl acetate fraction (EA) was chromatographed on silica gel
CC using a gradient of petroleum ether:acetone (100:0 to 0:100), to give 22 fractions. The fraction
EA3, eluted with petroleum ether:acetone (85:15), was rechromatographed on silica gel CC eluting
with petroleum ether:acetone (90:10) to give nine subfractions. The subfractions EA1.2 and EA1.3
contained the by-products BP1 and BP2 (60 and 20 mg, respectively). The fraction EA20, eluted
with petroleum ether:acetone (50:50), was analyzed by HPLC using a reversed phase column and
eluting with methanol:acetonitrile:water (4:1:5), to give four subfractions. The subfraction EA20.1,
EA20.2 and EA20.4 contained the byproduct BP3–BP5 (6, 40 and 13 mg, respectively). The fraction
obtained by extraction with water (W) was filtered on C18 silica gel CC with methanol and water
(Scheme 2). The methanol fraction (WM) was chromatographed on silica gel CC using a gradient of
methylene chloride:acetone (95:5 to 80:20), to give 9 fractions. The fraction WM1, eluted with methylene
chloride:acetone (95:5), contained the byproduct BP6 (17 mg) that was purified on TLC eluted with
petroleum ether:acetone (85:15). The fraction WM5, eluted with methylene chloride:acetone (85:15),
contained the byproduct BP7. It was rechromatographed on silica gel CC eluting with a hexane:acetone
gradient (100:0 to 65:35) to give 7 subfractions. The subfraction WM5.5 contained the byproduct BP7
(31 mg).
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Scheme 2. Isolation of seven identified DBPs.
3.3. Spectral Data
2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexyl hypochlorite (BP1). White powder. 1H-NMR
(499.6 MHz, CDCl3): δ 1.35 (m, 1H, H-3), 1.55 (m, 1H, H-4), 1.65 (m, 2H, H-4, H-6), 1.75 (m, 1H, H-5),
1.80 (m, 2H, H-3, H-5), 1.84 (m, 1H, H-2), 2.06 (d, J = 13.70, 2.40 Hz, 1H, H-7), 2.08 (m, 1H, H-6), 2.13
(s, 3H, H-9), 2.15 (s, 3H, H-10), 2.40 (d, J = 13.70, 4.50 Hz, 1H, H-7), 3.85 (s, 3H, OCH3), 6.77 (dd, J = 8.2,
2.4 Hz, 1H, H-4′), 7.05 (dd, J = 8.0, 2.2 Hz, 1H, H-6′), 7.16 (br s, 1H, H-2′), 7.24 (dd, J = 8.2, 8.0 Hz, 1H,
H-5′). 13C-NMR (125.62 MHz, CDCl3): δ 22.24 (C-5), 26.82 (C-3), 27.92 (C-4), 44.73 (C-2), 41.31 (C-6),
55.00 (OCH3), 61.55 (C-7), 77.00 (C-1), 47.72 (C-9, C-10), 111.25 (C-4′), 110.98 (C-2′), 117.36 (C-6′), 128.94
(C-5′), 152.00 (C-1′), 159.98 (C-3′). ESI-MS (positive ions): m/z calculated for C16H24ClNO2 m/z 297.82
[M]+ and 299.82 [M + 2]+; found 297.81 [M]+ and 299.80 [M + 2]+, 262.37 [M − Cl]+, 246.37 [M − OCl]+.
2-[Amino(hydroxyl)methyl]-1-(3-methoxyphenyl)cyclohexanol (BP2). White powder. 1H-NMR (499.6 MHz,
CDCl3): δ 1.18 (m, 1H, H-5), 1.26 (m, 1H, H-5), 1.43 (m, 1H, H-3), 1.54 (m, 1H, H-4), 1.65 (m, 1H, H-6),
1.75 (m, 1H, H-4), 1.85 (m, 1H, H-3), 2.01 (m, 1H, H-6), 2.15 (m, 1H, H-2), 3.83 (s, 3H, OCH3), 4.45
(m, 1H, H-7), 6.81 (dd, J = 8.2, 2.4 Hz, 1H, H-4′), 7.00 (dd, J = 8.0, 2.2 Hz, 1H, H-6′), 7.05 (br s, 1H, H-2′),
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7.29 (dd, J = 8.2, 8.0 Hz, 1H, H-5′). 13C-NMR (125.62 MHz, CDCl3): δ 20.91 (C-4), 26.23 (C-3), 26.95
(C-5), 32.70 (C-2), 40.38 (C-6), 55.21 (OCH3), 67.85 (C-7), 77.07 (C-1), 110.88 (C-2′), 111.97 (C-4′), 116.68
(C-6′), 129.26 (C-5′), 148.48 (C-1′), 159.52 (C-3′). ESI-MS (positive ions): m/z calculated for C14H21NO3
251.32 [M]+; found 251.30 [M]+.
2-Hydroxy-2-(3-methoxyphenyl)cyclohexanecarbaldehyde (BP3). White powder. 1H-NMR (499.6 MHz,
CDCl3): δ 1.63 (m, 1H, H-5), 1.72 (m, 1H, H-5), 2.03 (m, 3H, H-4, H-4, H-6), 2.31 (m, 1H, H-6), 3.85
(s, 3H, OCH3), 6.65 (s, 1H, H-2), 6.86 (dd, J = 7.8, 2.6 Hz, 1H, H-4′), 6.98 (dd, J = 7.8, 1.8 Hz, 1H, H-6′),
7.02 (br t, J = 1.9 Hz, 1H, H-2′), 7.31 (t, J = 8.0 Hz, 1H, H-5′), 9.61 (s, 1H, H-7). 13C-NMR (125.62 MHz,
CDCl3): δ 18.40 (C-5), 21.44 (C-4), 39.28 (C-6), 55.32 (OCH3), 77.10 (C-1), 111.34 (C-2′), 112.74 (C-4′),
117.61 (C-6′), 129.58 (C-5′), 143.50 (C-3), 150.71 (C-1′), 150.02 (C-2), 159.95 (C-3′), 192.90 (C-7). ESI-MS
(positive ions): m/z calculated for C14H18O3 234.29 [M]+; found 234.35 [M]+, 205.37 [M − CHO]+.
(4aS,8aS)-8a-(3-Methoxyphenyl)-3-methyloctahydro-2H-benzo[e][1,3]oxazine (BP4). White powder.
1H-NMR (499.6 MHz, CDCl3): δ 1.30 (m, 1H, H-3), 1.50 (m, 1H, H-5), 1.65 (m, 1H, H-4), 1.70 (m, 1H,
H-5), 1.80 (m, 1H, H-3), 1.90 (m, 1H, H-6), 1.94 (m, 1H, H-6), 2.01 (s, 3H, H-9), 2.31 (m, 1H, H-2), 2.38
(m, 1H, H-4), 2.42 (d, J = 13.0 Hz, 1H, H-7), 2.54 (d, J = 13.0 Hz, 1H, H-7), 3.62 (d, J = 8.6 Hz, 1H, H-10),
3.81 (s, 3H, OCH3), 4.20 (d, J = 8.6 Hz, 1H, H-10), 6.78 (dd, J = 8.2, 2.4 Hz, 1H, H-4′), 6.94 (dd, J = 8.0,
2.2 Hz, 1H, H-6′), 6.96 (br s, 1H, H-2′), 7.27 (dd, J = 8.2, 8.0 Hz, 1H, H-5′). 13C-NMR (125.62 MHz,
CDCl3): δ 22.07 (C-5), 25.54 (C-3), 27.59 (C-4), 35.13 (C-2), 40.36 (C-9), 42.70 (C-6), 55.20 (OCH3), 56.12
(C-7), 77.10 (C-1), 82.40 (C-10), 111.66 (C-4′), 112.18 (C-2′), 118.25 (C-6′), 129.54 (C-5′), 147.30 (C-1′),
160.00 (C-3′). ESI-MS (positive ions): m/z calculated for C16H23NO2 261.36 [M]+; found 261.34 [M]+.
6-Chloro-6,7-dihydroxy-1-(3-methoxyphenyl)decane-1,9-dione (BP5). White powder. 1H-NMR (499.6 MHz,
CDCl3): δ 1.80 (m, 2H, H-4), 1.83 (m, 2H, H-3), 2.28 (s, 3H, H-10), 2.35 (m, 2H, H-5), 2.95 (dd, J = 18.0,
9.0 Hz, 1H, H-8), 3.04 (t, J = 6.5 Hz, 2H, H-2), 3.18 (dd, J = 18.0, 2.0 Hz, 1H, H-8), 4.39 (d, J = 8.9 Hz, 1H,
H-7), 3.88 (s, 3H, OCH3), 7.13 (dd, J = 8.0, 2.4 Hz, 1H, H-4′), 7.40 (t, J = 8.0 Hz, 1H, H-5′), 7.51 (br s, 1H,
H-2′), 7.56 (dd, J = 8.0, 2.2 Hz, 1H, H-6′). 13C-NMR (125.62 MHz, CDCl3): δ 23.62 (C-4), 24.47 (C-3),
30.87 (C-10), 38.31 (C-2), 43.60 (C-5), 45.30 (C-8), 55.50 (OCH3), 74.07 (C-7), 96.27 (C-6), 112.40 (C-2′),
119.50 (C-4′), 120.71 (C-6′), 129.62 (C-5′), 138.28 (C-1′), 159.87 (C-3′), 199.69 (C-1), 208.13 (C-10). ESI-MS
(positive ions): m/z calculated for C17H23ClO5 342.81 [M]+ and 344.81 [M + 2]+; found 342.79 [M]+
and 344.80 [M + 2]+.
N-[(2-Hydroxy-2-(3-methoxyphenyl)cyclohexyl)methyl]-N-methylformamide (BP6). White powder. 1H-NMR
(499.6 MHz, CDCl3): δ 1.31 (m, 1H, H-3), 1.41 (m, 1H, H-5), 1.58 (m, 1H, H-3), 1.60 (m, 1H, H-6), 1.70
(m, 2H, H-4, H-5), 1.75 (m, 1H, H-6), 1.90 (m, 1H, H-4), 2.26 (m, 1H, H-2), 2.59 (s, 3H, H-9), 2.71
(d, J = 14.80, 3.00 Hz, 1H, H-7), 3.08 (d, J = 14.80, 10.40 Hz, 1H, H-7), 3.79 (s, 3H, OCH3), 6.73 (dd, J = 8.2,
2.4 Hz, 1H, H-4′), 7.01 (dd, J = 8.0, 2.2 Hz, 1H, H-6′), 7.18 (br s, 1H, H-2′), 7.26 (dd, J = 8.2, 8.0 Hz, 1H,
H-5′), 7.79 (s, 1H, H-10). 13C-NMR (125.62 MHz, CDCl3): δ 21.80 (C-5), 25.41 (C-3), 25.63 (C-4), 29.76
(C-9), 41.54 (C-2), 43.30 (C-6), 50.68 (C-7), 55.23 (OCH3), 74.18 (C-1), 111.47 (C-2′), 111.72 (C-4′), 116.85
(C-6′), 129.45 (C-5′), 150.08 (C-1′), 159.74 (C-3′), 163.13 (C-10). ESI-MS (positive ions): m/z calculated
for C16H23NO3 277.36 [M]+; found 277.38 [M]+.
4-(3-Methoxyphenyl)-2-nitrosooctahydro-1H-isoindol-4-ol (BP7). White powder. 1H-NMR (499.6 MHz,
CDCl3): δ 1.62 (m, 1H, H-5), 1.65 (m, 2H, H-4, H-6), 1.70 (m, 1H, H-5), 1.80 (m, 1H, H-6), 1.90 (m, 1H,
H-4), 1.95 (m, 1H, H-3), 2.15 (m, 1H, H-2), 2.66 (m, 1H, H-9), 2.70 (m, 1H, H-9), 2.73 (d, J = 14.0 Hz,
1H, H-7), 2.75 (d, J = 14.0 Hz, 1H, H-7), 3.82 (s, 3H, OCH3), 6.77 (dd, J = 8.2, 2.4 Hz, 1H, H-4′), 7.03
(dd, J = 8.0, 2.2 Hz, 1H, H-6′), 7.06 (br s, 1H, H-2′), 7.28 (dd, J = 8.2, 8.0 Hz, 1H, H-5′). 13C-NMR (125.62
MHz, CDCl3): δ 21.96 (C-5), 25.81 (C-3), 26.11 (C-4), 44.53 (C-2), 41.62 (C-6), 55.16 (OCH3), 54.00 (C-7),
77.50 (C-1), 67.40 (C-9), 111.59 (C-4′), 110.71 (C-2′), 117.05 (C-6′), 129.13 (C-5′), 149.66 (C-1′), 160.22
(C-3′). ESI-MS (positive ions): m/z calculated for C15H20N2O3 276.33 [M]+; found 276.31 [M]+, 246.30
[M − NO]+, 219.29 [M – NO − HCN]+.
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3.4. Ecotoxicity Assays
TRA and its products were dissolved in 0.01% dimethyl sulfoxide (DMSO) and further diluted
in synthetic freshwater to make stock solutions [34]. The acute bioluminescence inhibition assay was
carried out using Aliivibrio fischeri (NRRL-B-11177), according to ISO 2007 [37]. The luminescence was
measured with a Microtox® analyzer (Model 500, AZUR Environmental, Carlsbad, CA, USA) after
30 min at 15 ◦C. Tests were carried out in triplicate. Data were analyzed with Microtox Omni software
(version 1.18AZUR Environmental, Carlsbad, CA, USA) and the result expressed as percentage of
bioluminescence inhibition (%). The chronic growth inhibition test with Raphidocelis subcapitata was
carried out according to ISO 2012 [38]. The cultures were kept in Erlenmeyer flasks. The initial
inoculum contained 104 cells/mL. The specific growth inhibition rate was calculated considering 3
replicates exposed at 24 ± 1 ◦C for 72 h under continuous illumination (120–60 µein/m2s). Effect data
were expressed as percentage of growth inhibition [39].
Acute toxicity tests with Daphnia magna were carried out according to ISO 2007 [37]. Newborn
daphnids (<24 h old) were exposed in four replicates for 24 and 48 h at 20 ± 1 ◦C in the dark. Toxicity
was expressed as the percentage of dead organisms [40]. Toxicity was expressed as the median effective
concentration (EC50) along with 95% confidence limit values considering parametric or non-parametric
methods. Two-way analysis of variance was carried out followed by Tukey’s post hoc analysis after
testing normality and homoscedasticity of data distributions. Statistical analysis and graphs were done
using Microsoft® Excel 2013/XLSTAT©-Pro (Version 7.2, 2003, Addin soft, Inc., Brooklyn, NY, USA).
4. Conclusions
This paper investigated the fate of TRA following disinfection treatment by chlorination and the
ecotoxicity of this drug and its disinfection by-products. The reaction was carried out simulating the
conditions of a typical wastewater plant, using an excess of sodium hypochlorite. TRA undergoes
more than 70% of degradation but the treatment did not give rise the mineralization but rather
induces the transformation of TRA itself into at least seven by-products, two of them chlorinated.
Consistent with observations of previous studies based on toxic risk associated with hypochlorite
treatment [22–24,40], the transformation by-products of TRA were confirmed to present higher toxicity
than TRA. In particular, these data suggest that TRA chlorination has the potential to produce
by-products which are more harmful than TRA. Considering the large consumption of this drug
in both Europe and America, and the consistent amounts of it found in many effluents and also in
lakes and rivers, it is imperative to consider the chlorination of TRA hazardous for its environmental
impact and for human health. For a complete degradation of this pollutant it could be useful a longer
chlorination process were applied or it were performed twice [22].
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